Inc., USA (Glenmark) has announced the launch of Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), further strengthening its presence in the ophthalmic segment. This latest product is ...

According to IQVIA, sales data for the 12-month period ending December 2024, the Xalatan Ophthalmic Solution achieved annual ...

Glenmark Pharmaceuticals said that US-based Glenmark Pharmaceuticals Inc. has launched Latanoprost Ophthalmic Solution.

According to IQVIA sales data for the 12-month period ending December 2024, the Xalatan Ophthalmic Solution, 0.005% market achieved annual sales of approximately $113.5 million.

Despite an improved HIV PrEP-to-need ratio from 2018 to 2021, PrEP use relative to need was lower in certain populations, ...

According to Statifacts, the global clinical trials market size is calculated at USD 126.30 billion in 2025 and is expected ...

IQVIA (NYSE:IQV – Get Free Report) had its price target lifted by Morgan Stanley from $245.00 to $250.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has an “overweight” ...

AAM said the report highlights that 90% of the brand biologics scheduled to lose exclusivity in the next 10 years do not have ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Glenmark Pharmaceuticals Ltd on Wednesday said its US arm has launched the generic version of Clindamycin Phosphate foam, an.